Match tier
Likely match
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-16
T
Thomas Kieber‐Emmons
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Faculty Researcher
42 h-index
243 pubs
5,583 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Thomas Kieber‐Emmons' research focuses on harnessing antibody polyspecificity for cancer immunotherapy and understanding immune responses to vaccines. His work includes designing bioactive peptides based on antibody structures and investigating antibody reactivity against tumor-associated antigens. Kieber‐Emmons has also published on the P10s-PADRE vaccine's effects in breast cancer patients and discusses topics related to vaccine risk communication and expert panel discussions on antigenic sin.
Metrics
- h-index: 42
- Publications: 243
- Citations: 5,583
Selected Publications
-
When Reassurance Falls Short: Rethinking Vaccine Risk Communication (2025)
-
Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment (2024)
-
Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine (2024)
-
Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine (2023)
-
Thoughts on mRNA Vaccine Response (2023)
-
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen (2023)
-
Harnessing Antibody Polyspecificity for Cancer Immunotherapy (2022)
-
Living with Endemic COVID-19 (2022)
-
Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients (2022)
-
Cancer Patients and COVID-19 Vaccination (2021)
-
P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses (2021)
-
Expert Panel Discussion on Antigenic Sin (2021)
-
Antibodies are the Forefront of Today's Medicine (2021)
-
Antibodies in the Thick of Things (2021)
-
“Why Not Hybridomas” (2021)
Collaboration Network
Top Collaborators
Fariba Jousheghany
University of Arkansas for Medical Sciences
6 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
Showing 5 of 6 shared publications
Eric R. Siegel
University of Arkansas for Medical Sciences
6 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
Showing 5 of 6 shared publications
Behjatolah Monzavi‐Karbassi
University of Arkansas for Medical Sciences
6 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
Showing 5 of 6 shared publications
Issam Makhoul
4 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
Bernice Nounamo
University of Arkansas for Medical Sciences
4 shared publications
In database
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
- Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment
Saddam Mohammed Ibrahim
University of Arkansas for Medical Sciences (US)
2 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Muhammad Abu‐Rmaileh
University of Arkansas for Medical Sciences (US)
2 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Lora J. Rogers
University of Arkansas for Medical Sciences
2 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Sergio Piña‐Oviedo
University of Arkansas for Medical Sciences (US)
2 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Ginell R. Post
University of Arkansas for Medical Sciences
2 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Eric P. Brown
1 shared publication
- Expert Panel Discussion on Antigenic Sin
Peter L. Nara
1 shared publication
- Expert Panel Discussion on Antigenic Sin
Heinz Köhler
1 shared publication
- Expert Panel Discussion on Antigenic Sin
John J. Lee
University of Arkansas for Medical Sciences (US)
1 shared publication
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
J. Thaddeus Beck
University of Arkansas for Medical Sciences (US)
1 shared publication
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
Similar Researchers
Based on overlapping research topics
Bahaa Mustafa
University of Arkansas for Medical Sciences
Monoclonal and Polyclonal Antibodies Research
Cancer Immunotherapy and Biomarkers
Immune Response and Inflammation
Kaori Yamasaki
University of Arkansas at Fayetteville
Vaccine Coverage and Hesitancy
SARS-CoV-2 and COVID-19 Research
Health Literacy and Information Accessibility
Anna Gentry
University of Arkansas at Fayetteville
Vaccine Coverage and Hesitancy
SARS-CoV-2 and COVID-19 Research
Health Literacy and Information Accessibility
Behjatolah Monzavi‐Karbassi
University of Arkansas for Medical Sciences
Monoclonal and Polyclonal Antibodies Research
Cancer Immunotherapy and Biomarkers
Immune Response and Inflammation
Teresa Evans
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Immune Response and Inflammation
Vaccine Coverage and Hesitancy
Pravin Parajuli
National Center for Toxicological Research
Immune Response and Inflammation
SARS-CoV-2 and COVID-19 Research
Protein Structure and Dynamics